Securities Act (Neuren Pharmaceuticals Limited) Exemption Amendment Notice 2009

  • expired
  • Securities Act (Neuren Pharmaceuticals Limited) Exemption Amendment Notice 2009: expired, on 1 July 2011, pursuant to clause 3 of the Securities Act (Neuren Pharmaceuticals Limited) Exemption Notice 2006 (SR 2006/143).

Reprint
as at 1 July 2011

Coat of Arms of New Zealand

Securities Act (Neuren Pharmaceuticals Limited) Exemption Amendment Notice 2009

(SR 2009/200)

  • Securities Act (Neuren Pharmaceuticals Limited) Exemption Amendment Notice 2009: expired, on 1 July 2011, pursuant to clause 3 of the Securities Act (Neuren Pharmaceuticals Limited) Exemption Notice 2006 (SR 2006/143).


Note

Changes authorised by section 17C of the Acts and Regulations Publication Act 1989 have been made in this reprint.

A general outline of these changes is set out in the notes at the end of this reprint, together with other explanatory material about this reprint.

This notice is administered by the Securities Commission.


Pursuant to the Securities Act 1978, the Securities Commission gives the following notice (to which is appended a statement of reasons of the Securities Commission).

Notice

1 Title
  • This notice is the Securities Act (Neuren Pharmaceuticals Limited) Exemption Amendment Notice 2009.

2 Commencement
  • This notice comes into force on its notification in the Gazette.

3 Principal notice amended
4 Requirements for share purchase plan
  • (1) Clause 5(1)(h) is amended by omitting A$5,000 and substituting A$15,000.

    (2) Clause 5(2) is amended by omitting A$5,000 in each place where it appears and substituting in each case A$15,000.

Dated at Wellington this 15th day of July 2009.

The Common Seal of the Securities Commission was affixed in the presence of:

[Seal]

J Diplock,
Chairperson.


Statement of reasons

This notice, which comes into force on its notification in the Gazette, amends the Securities Act (Neuren Pharmaceuticals Limited) Exemption Notice 2006 by increasing the maximum value of equity securities that can be offered by Neuren Pharmaceuticals Limited (Neuren) to each security holder under a share purchase plan from A$5,000 to A$15,000.

The Securities Commission considers that it is appropriate to amend the principal notice because—

  • Neuren is a New Zealand incorporated company that is listed on the Australian Stock Exchange (ASX). It is not listed in New Zealand. Approximately 20% of Neuren's shareholders are resident in New Zealand. As an ASX listed company, Neuren can offer its shareholders the ability to participate in share purchase plans under a class order made by the Australian Securities and Investments Commission (CO 09/425). The maximum value of shares that can be offered by a company under that class order has recently been raised from A$5,000 to A$15,000. This amendment recognises that the principal market for share offers by Neuren is Australia, and that the principal regulation for these offers is Australian law:

  • raising the annual per-shareholder cap under the principal notice from A$5,000 to A$15,000 will allow both Australian and New Zealand shareholders of Neuren to participate in share purchase plans on the same terms as shareholders of other ASX listed companies.


Issued under the authority of the Acts and Regulations Publication Act 1989.

Date of notification in Gazette: 17 July 2009.


Contents

  • 1General

  • 2Status of reprints

  • 3How reprints are prepared

  • 4Changes made under section 17C of the Acts and Regulations Publication Act 1989

  • 5List of amendments incorporated in this reprint (most recent first)


Notes
1 General
  • This is a reprint of the Securities Act (Neuren Pharmaceuticals Limited) Exemption Amendment Notice 2009. The reprint incorporates all the amendments to the notice as at 1 July 2011, as specified in the list of amendments at the end of these notes.

    Relevant provisions of any amending enactments that contain transitional, savings, or application provisions that cannot be compiled in the reprint are also included, after the principal enactment, in chronological order. For more information, see http://www.pco.parliament.govt.nz/reprints/ .

2 Status of reprints
  • Under section 16D of the Acts and Regulations Publication Act 1989, reprints are presumed to correctly state, as at the date of the reprint, the law enacted by the principal enactment and by the amendments to that enactment. This presumption applies even though editorial changes authorised by section 17C of the Acts and Regulations Publication Act 1989 have been made in the reprint.

    This presumption may be rebutted by producing the official volumes of statutes or statutory regulations in which the principal enactment and its amendments are contained.

3 How reprints are prepared
  • A number of editorial conventions are followed in the preparation of reprints. For example, the enacting words are not included in Acts, and provisions that are repealed or revoked are omitted. For a detailed list of the editorial conventions, see http://www.pco.parliament.govt.nz/editorial-conventions/ or Part 8 of the Tables of New Zealand Acts and Ordinances and Statutory Regulations and Deemed Regulations in Force.

4 Changes made under section 17C of the Acts and Regulations Publication Act 1989
  • Section 17C of the Acts and Regulations Publication Act 1989 authorises the making of editorial changes in a reprint as set out in sections 17D and 17E of that Act so that, to the extent permitted, the format and style of the reprinted enactment is consistent with current legislative drafting practice. Changes that would alter the effect of the legislation are not permitted.

    A new format of legislation was introduced on 1 January 2000. Changes to legislative drafting style have also been made since 1997, and are ongoing. To the extent permitted by section 17C of the Acts and Regulations Publication Act 1989, all legislation reprinted after 1 January 2000 is in the new format for legislation and reflects current drafting practice at the time of the reprint.

    In outline, the editorial changes made in reprints under the authority of section 17C of the Acts and Regulations Publication Act 1989 are set out below, and they have been applied, where relevant, in the preparation of this reprint:

    • omission of unnecessary referential words (such as of this section and of this Act)

    • typeface and type size (Times Roman, generally in 11.5 point)

    • layout of provisions, including:

      • indentation

      • position of section headings (eg, the number and heading now appear above the section)

    • format of definitions (eg, the defined term now appears in bold type, without quotation marks)

    • format of dates (eg, a date formerly expressed as the 1st day of January 1999 is now expressed as 1 January 1999)

    • position of the date of assent (it now appears on the front page of each Act)

    • punctuation (eg, colons are not used after definitions)

    • Parts numbered with roman numerals are replaced with arabic numerals, and all cross-references are changed accordingly

    • case and appearance of letters and words, including:

      • format of headings (eg, headings where each word formerly appeared with an initial capital letter followed by small capital letters are amended so that the heading appears in bold, with only the first word (and any proper nouns) appearing with an initial capital letter)

      • small capital letters in section and subsection references are now capital letters

    • schedules are renumbered (eg, Schedule 1 replaces First Schedule), and all cross-references are changed accordingly

    • running heads (the information that appears at the top of each page)

    • format of two-column schedules of consequential amendments, and schedules of repeals (eg, they are rearranged into alphabetical order, rather than chronological).

5 List of amendments incorporated in this reprint (most recent first)
  • Securities Act (Neuren Pharmaceuticals Limited) Exemption Notice 2006 (SR 2006/143): clause 3